Paramagnetic contrast agent gadolinium-based and used for T1-weighted magnetic resonance imaging (MRI) of the liver. In the dynamic and delayed images proviron 25mg improves the detection of liver focal lesions (including their number, size, segmental distribution and visualization) and provides additional data on the characterization and classification of focal liver lesions, thus increasing the accuracy of diagnosis.
The effect of contrast enhancement due to the stability of the complex gadolinium. The paramagnetic efficacy or relaxation ability, determined from the effect on spin-lattice relaxation time of protons in plasma is about 8.7 l / mmol / sec at pH 7, a temperature of 39 ° C, and the magnetic field strength of 0.47 T. It is only slightly It depends on the strength of the magnetic field. When scanning using T1-weighted pulse sequences shortening of the spin-lattice relaxation time of the excited nuclei caused gadolinium ions leads to an increase in signal intensity and thus to enhance the image contrast of certain tissues.
EOB-DTPA forms a stable complex with the paramagnetic gadolinium ion with extremely high thermodynamic stability (the log the K Gdl = -23.46). Gd-EOB-DTPA is hydrophilic compound having high water solubility. Availability etoksibenzilnoy group attached complex lipophilic properties.
After intravenous administration, the active substance diffuses rapidly into the intercellular space. Seven days after the intravenous injection of Gd-EOB-DTPA in rats and dogs is determined substantially below 1% of the administered dose, while the highest concentration of the substance detected in the kidney and liver.
The active substance passes through the intact blood-brain proviron 25mg barrier and only slightly diffuses through the placental barrier.
Half-life of Gd-EOB-DTPA from human serum was 1.0 ± 0.1 hours, and substantially independent of the dose received. T1 / 2 period in the terminal phase is 1.65 ± 0.23 hours or less. Pharmacokinetics observed is linear up to a dose of 0.4 ml / kg (100 mol / kg) of body weight.
Gd-EOB-DTPA is completely eliminated from the body in equal proportions by the kidneys and hepatobiliary system.
• Characteristics in patients
In severe renal dysfunction and hepatic excretion character changed accordingly. Patients with severe hepatic impairment serum half-life is increased slightly, whereas patients with severe renal failure (requiring hemodialysis) half-life is markedly increased.
Indications for use
of intravenous Primovist is intended solely for diagnostic purposes.
Primovist is a paramagnetic contrast agent gadolinium-based and used for T1-weighted magnetic resonance imaging (MRI) of the liver. In the dynamic and delayed images Primovist improves the detection of liver focal lesions (including their number, size, segmental distribution and visualization) and provides additional data on the characterization and classification of focal liver lesions, thus increasing the accuracy of diagnosis.
Hypersensitivity to the active substance or to any of the supporting components of the drug.
Patients with allergic / pseudoallergic reactions to any allergen in the past, as well as patients with asthma may be at increased risk of severe reactions. Most of these reactions are observed within an hour after administration. However, as with other contrast media of this class, in rare cases delayed reactions may develop (from several hours to days).
• Cardiovascular disease
Data on the introduction Primovista patients with severe cardiovascular disease are limited, so in these cases it is necessary to be careful.
Use during pregnancy, lactation and pediatric
Animal studies showed no risk of teratogenic effects or effects on fertility, embryo, as well as pre- and postnatal development. Primovist should be administered to pregnant women only after a comprehensive evaluation of benefit / risk ratio.
Tests on animals have shown that Primovist in a minimal volume (less than 0.5% of the administered dose) passes into breast milk. Primovist should be administered to nursing women only after a comprehensive evaluation of benefit / risk ratio.
• Children under 18 years
Clinical experience of use in patients under 18 years of absence.
Dosing and Administration
• General rules of procedure
necessary to comply with the general safety precautions for magnetic resonance imaging. We do not recommend carrying out magnetic resonance imaging in the presence of a pacemaker in a patient and / or ferromagnetic implants.
Within two hours before the examination the patient should refrain from eating to reduce the risk of aspiration, since all the contrast agents can cause side effects such as nausea and vomiting.
Wherever possible, during the introduction of proviron 25mg contrast medium into the patient must be in a horizontal position. After injection should monitor the condition of the patient for at least 30 minutes, as the use of contrast agents experience shows that the majority of adverse events evolving during this period.